Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,763 DKK | -0.87% |
|
-2.27% | -18.10% |
11:07am | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
10:33am | AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.10% | 16.24B | |
+16.13% | 122B | |
+19.65% | 113B | |
+19.51% | 26.49B | |
-23.84% | 19.4B | |
-45.95% | 15.15B | |
-19.28% | 15.4B | |
+63.81% | 14.93B | |
+1.94% | 13.52B | |
+116.04% | 10.79B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating